An open label multi-site phase II clinical trial of dose escalated sunitinib malate given
orally once daily on days 1-28 of each 42-day cycle. Treatment will be continued until there
is either disease progression or cumulative or acute toxicity which in the opinion of the
treating physician compromises the ability of the patient to receive treatment or patient
desire to stop treatment.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute